"The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery," one specialist said in a statement.
A team of cardiologists and cardiac surgeons collaborated on the new analysis, reviewing data from more than 50,000 patients and developing a new risk model for clinicians.
Gulati, an award-winning cardiologist and author, first joined Cedars-Sinai in 2022. She is also the president of the American Society for Preventive Cardiology.
Reducing total calorie intake and minimizing large meals, on the other hand, were both linked to improved weight loss. The study followed participants for an average of 6.3 years.
Contrast-associated acute kidney injury is a significant problem in cardiology, especially among patients undergoing percutaneous coronary intervention. Can EHR-generated alerts make an impact?
Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.
The Neovasc Reducer System is designed to treat the symptoms of refractory angina by altering a patient's blood flow.
Shockwave Medical's decision to acquire Neovasc is based largely on the potential of the Neovasc Reducer System, a solution designed to treat the symptoms of refractory angina by altering a patient's blood flow.
Primary aldosteronism (PA) is one the single most common causes of hypertension, but identifying patients with PA—and knowing which ones may benefit from a surgical treatment—can be quite challenging.
